CMR in Cardiac Sarcoidosis

Revision as of 05:28, 1 October 2012 by Shankar Kumar (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Cardiac involvement is found at autopsy in 20-30% of patients diagnosed with sarcoid and is felt to play a role in sudden death. Recent research has shown that one can find evidence of cardiac sarcoid on MRI in patients with normal echocardiograms.

Echocardiography in cardiac sarcoid shows septal thinning, systolic and diastolic LV dysfunction. There are multiple findings on MR in patients with cardiac sarcoidosis. MR may help with early diagnosis of cardiac sarcoidosis.

ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance (DO NOT EDIT)

CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including

  • evaluation of dilated cardiomyopathy in the setting of normal coronary arteries,
  • patients with positive cardiac enzymes without obstructive atherosclerosis on angiography,
  • patients suspected of amyloidosis or other infiltrative diseases,
  • hypertrophic cardiomyopathy,
  • arrhythmogenic right ventricular dysplasia, or
  • syncope or ventricular arrhythmia.

Delayed hyperenhancement

Delayed hyperenhancement is consistent with inflammatory or fibrotic areas. Specifically, the regions of hyperenhancement in patients with sarcoidosis do not correspond to a coronary artery territory.

IMAGE

In a study by Patel et al of 58 consecutive patients with biopsy proven systemic sarcoidosis patients had a two fold higher rate of cardiac involvement by CMR diagnosis than by the Japanese Ministry of Health clinical criteria.

  • Hyperenhancement was found in the mid-myocardial wall or epicardium (ie non-ischemic)

It has also been shown that contrast enhancement decreases in these patients following steroid therapy. (Shimada et al.)


LV dysfunction

IMAGE


Contrast accumulation

This typically occurs in the intramyocardial and subepicardial layers

IMAGE


Transmural scarring and thinning of the basal septum

Transmural scarring and thinning of the basal septum is a common finding in patients with cardiac sarcoidosis.

IMAGE

Javier Sanz reported on a 47 year old woman with recent diagnosis of sarcoidisis. She underwent cardiac MR which revealed transmural scarring.

Pubmed image1 - reference Sanz, Javier in Eur Heart Jour


Endomyocardial biopsy subsequently showed areas of focal necrosis that could explain the MR findings.

Ventricular Tachycardia and Cardiac Sarcoidosis

A clinical vignette published by Redheuil and collegues showed the association of ventricular tachycardia and cardiac sarcoidosis using MR to show the relationship.

A 44 year old female with histologically proven pulmonary and mediastinal sarcoidosis who presented with palpitations followed by syncope.

MR findings were as follows:

  • Marked delayed enhancement of the basal lateral wall of the RV, basal anteroseptal and basal, mid LV and apical anterior epicardium of the LV.
  • Endocavitary ventricular stimulation induced 2 VT morphologies. The first was compatible with VT originating from the basal lateral wall of the RV and the second was compatible with VT originating from teh basal anteroseptal and or anterior segments of the LV.

References

Shimada, et al. Diagnosis of Cardiac Sarcoidosis and Evaluation of the Effects of Steroid Therapy by Gadolinium DTPA-Enhanced Magnetic Resonance Imaging. American Journal of Medicine. 2001. 110;520.

Redheuil, et al. Ventricular tachycardia and cardiac sarcoidosis: correspondence between MRI and electrophysiology. Eur Heart Journal. 2005.

Sanz et al. Cardiac Sarcoidosis detected with magnetic resonance imaging. Eur. Heart Journal. 2006.

Template:WikiDoc Sources